SLC7A5 and neoplasm: A tempting speculation is that, when combined with other anti-angiogenic agents, administration of LAT1 inhibitors would suppress the compensatory paracrine secretion of pro-angiogenic factors from tumor cells, through the down-regulation of protein synthesis in tumor cells.